Skip to main content

Invasive Fungal Disease

2
Pipeline Programs
9
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 9 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
IsavuconazolePhase 4Small Molecule1 trial
FungiScope - A Global Emerging Fungal Infection RegistryN/A
Active Trials
NCT05630976Completed70Est. Apr 2025
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Liposomal amphotericin BPhase 31 trial
Active Trials
NCT01259713Completed355Est. Jan 2014
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Amphotericin B colloidal dispersion（ABCD）N/A1 trial
Active Trials
NCT05116059Unknown500Est. Jan 2023
Basilea Pharmaceutica
Basilea PharmaceuticaSwitzerland - Allschwil
1 program
FungiScopeN/A
Matinas Biopharma
Matinas BiopharmaBEDMINSTER, NJ
1 program
FungiScope - A Global Emerging Fungal Infection RegistryN/A1 trial
Active Trials
NCT01731353Recruiting1,000Est. Dec 2026
Cidara Therapeutics
Cidara TherapeuticsCA - San Diego
1 program
FungiScope - A Global Emerging Fungal Infection RegistryN/A
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
FungiScope - A Global Emerging Fungal Infection RegistryN/A
F2G
F2GUK - Manchester
1 program
FungiScope - A Global Emerging Fungal Infection RegistryN/A
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
Liposomal amphotericin BPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerIsavuconazole
Kite PharmaLiposomal amphotericin B
UNION therapeuticsAmphotericin B colloidal dispersion（ABCD）
Matinas BiopharmaFungiScope - A Global Emerging Fungal Infection Registry

Clinical Trials (4)

Total enrollment: 1,925 patients across 4 trials

NCT05630976PfizerIsavuconazole

Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

Start: Feb 2023Est. completion: Apr 202570 patients
Phase 4Completed
NCT01259713Kite PharmaLiposomal amphotericin B

Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Chemotherapy for Acute Lymphoblastic Leukemia

Start: Apr 2011Est. completion: Jan 2014355 patients
Phase 3Completed
NCT05116059UNION therapeuticsAmphotericin B colloidal dispersion（ABCD）

To Evaluate the Efficacy and Safety of ABCD in the Treatment of IFD

Start: Oct 2021Est. completion: Jan 2023500 patients
N/AUnknown
NCT01731353Matinas BiopharmaFungiScope - A Global Emerging Fungal Infection Registry

FungiScope - A Global Emerging Fungal Infection Registry

Start: Mar 2003Est. completion: Dec 20261,000 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,925 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.